Heart failure treatment strategies are emphasized based off recent clinical trial data.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses knowing when to deviate from guideline-directed heart failure therapy, emphasizing the expert clinician’s role in individualizing care. Albert notes renal concerns previously limited use of renin-angiotensin-aldosterone system (RAAS) inhibitors and mineralocorticoid receptor antagonists (MRAs), but current evidence shows overall kidney benefits with angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors despite initial changes in function. Understanding drugs’ mechanisms and adverse effect profiles prevents inappropriate discontinuation. Axsom emphasizes how multidisciplinary teams help monitor patients starting new therapies, allowing providers to “ride out” transient changes. Desai stresses that all clinicians should initiate guideline-directed treatments using standard protocols. Axsom reviews data showing the ARNIs (sacubitril-valsartan) reduce mortality by 16% versus angiotensin-converting enzyme (ACE) inhibitors in heart failure with reduced ejection fraction (HFrEF), leading to its favored status. However, it should not be started in unstable, symptomatic patients. Desai adds that this mortality benefit was against active comparators, not placebo, underscoring the need to convert stable ACE inhibitor patients to ARNI therapy. Overall, expertise means maximizing evidence-based therapies through urgent optimization, not just following old habits. But multidisciplinary teams support appropriate individualization when challenges arise.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More